Polyclonal anti-thymocyte globulins (ATGs) are widely used in allogeneic stem cell transplantation (allo-SCT) for GvHD prophylaxis. ATGs exerted anti-tumor effects in in vitro experiments, but in vivo studies are lacking. We experienced a case of relapsed AML with cells positive for CD7 who underwent haploidentical SCT and unexpectedly achieved a significant reduction of AML cells in the peripheral blood after receiving ATGs before the administration of other drugs in the conditioning regimen. This patient achieved long-term survival after haploidentical SCT. To assess the impact of ATGs on clinical outcomes in patients with AML, we performed a retrospective analysis of allo-SCT for relapsed/refractory AML and divided 132 patients into four groups according to the expression of CD7 in AML cells and use of ATGs as part of the conditioning regimen, as follows: CD7-positive ATG group (n = 15), CD7-positive no-ATG group (n = 32), CD7-negative ATG group (n = 19), and CD7-negative no-ATG group (n = 66). The overall survival rates in the CD7-positive ATG group were significantly higher than those in the CD7-positive no-ATG group, whereas these rates did not differ statistically between the CD7-negative ATG and CD7-negative no-ATG groups. Our results indicate a possible anti-leukemic effect of ATGs against CD7-positive AML in humans.
Introduction
Polyclonal anti-thymocyte globulins (ATGs) are widely used to prevent and treat graft-versus-host disease (GvHD) in allogeneic stem cell transplantation (allo-SCT) [1] [2] [3] . Several prospective randomized clinical trials have demonstrated the efficacy of ATGs in reducing the risk of GvHD without compromising overall survival (OS) after allo-SCT [4] [5] [6] . It is still unclear why ATGs did not increase the risk of relapse or progression while ATGs significantly reduced the risk of GvHD [4, 5, 7, 8] .
ATGs efficiently deplete T cells through various mechanisms such as complement-dependent and cellmediated cytotoxicity or via the induction of apoptosis [9] . Intriguingly, several in vitro studies demonstrated that ATGs had anti-leukemic effects [10] [11] [12] [13] [14] , although there is minimal evidence of such effects in vivo.
A proportion of acute myeloid leukemia (AML) cells aberrantly express lymphoid surface markers such as CD2, CD3, CD4, CD5, CD7, CD8, and CD25 [15] [16] [17] [18] . Several studies showed that aberrant expression of lymphoid marker CD7 in AML was associated with an inferior clinical outcome [19] [20] [21] . CD7 and other markers are expressed on thymocytes, and were reported to be recognized by ATGs [22, 23] . Therefore, it would be reasonable to assume that ATGs could efficiently target AMLs with such aberrant lymphoid surface markers.
At our institute, we experienced a case of relapsed AML with CD7 who underwent haploidentical SCT and unexpectedly demonstrated a significant reduction of AML cells in the peripheral blood (PB) after receiving ATGs before the administration of other drugs in the conditioning regimen.
This patient achieved long-term survival after allo-SCT. This remarkable finding suggested that ATGs may have anti-leukemic effects in vivo and may possibly relate to the aberrant expression of lymphoid markers. To clarify the impact of ATGs, we retrospectively analyzed the clinical outcomes of 132 patients with relapsed/refractory AML who underwent allo-SCT at our institute, focusing on the use of ATGs and various surface markers, including CD7.
Materials and methods

Study design, inclusion criteria, clinical evaluation, and data collection
This study was approved by the Institutional Review Board of the National Cancer Center, Tokyo, Japan. This was a single-center retrospective study of consecutive patients with relapsed/refractory AML who received allo-SCT from 2000 to 2015. We divided 132 patients with relapsed/ refractory AML into four groups according to the expression of CD7 on AML cells and the use of ATG in the conditioning regimen, as follows: CD7-positive ATG group (n = 15), CD7-positive no-ATG group (n = 32), CD7-negative ATG group (n = 19), and CD7-negative no-ATG group (n = 66) (individual patient data in the CD7-positive ATG group are available in Supplementary Table 1 and  Supplementary Table 2 ). The ATG types and doses were as follows: Thymoglobulin ® at a total dose of 1.0 mg/kg (n = 1), 1.5 mg/kg (n = 1), 2.5 mg/kg (n = 9), 10.0 mg/kg (n = 2), Lymphoglobulin ® at a total dose of 45 mg/kg (n = 1), ATG-Fresenius ® at a total dose of 5 mg/kg (n = 1) in the CD7-positive ATG group; and Thymoglobulin ® at a total dose of 1.0 mg/kg (n = 1), 1.5 mg/kg (n = 5), 2.5 mg/kg (n = 7), 3.0 mg/kg (n = 1), 10 mg/kg (n = 2), Lymphoglobulin ® at a total dose of 45 mg/kg (n = 1), ATG-Fresenius ® at a total dose of 5 mg/kg (n = 2) in the CD7-negative ATG group. We excluded cases with acute promyelocytic leukemia and those without any available flow cytometry data. Cytogenetic risk stratification based on the Disease Risk Index led to classification of AML with t(8;21), inv (16) , and t(15;17) as favorable, AML with complex karyotype (four or more abnormalities) as adverse, and AML with any other abnormalities as intermediate [24] . Multiparameter flow cytometry in combination with a CD45/side scatter gating strategy was used to analyze the expression of surface antigens. In this study, the expression of CD2, CD3, CD4, CD5, CD7, CD8, CD56, and CD79a on AML cells was considered positive if more than 40% of the cells were stained.
Statistical analysis
Fisher's exact test was used to compare differences in the distribution of patient characteristics. The probabilities of OS and relapse-free survival (RFS) were calculated by the Kaplan-Meier method. Comparison of survival curves was performed using the log-rank test. A Cox proportionalhazards regression model was used to analyze OS and RFS. The cumulative incidences of non-relapse mortality (NRM), relapse, acute GvHD (aGvHD), and chronic GvHD (cGvHD) were evaluated using Gray's method. In the competing risk models, relapse was defined as the competing risk for NRM, and NRM was used as the competing risk for relapse. For aGvHD or cGvHD, relapse and death before these events were defined as the competing risks. [28] . In terms of the type of ATG, after the approval of Thymoglobulin ® in 2008 in Japan, most patients received Thymoglobulin ® . The statistical analyses were carried out using the EZR software package (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing, version 3.2.2) [29] . More precisely, it is a modified version of R commander (version 2.2-3) that was designed to add statistical functions that are frequently used in biostatistics. For all analyses, a two-sided P < 0.05 was considered statistically significant.
Results
Case report
We describe a 50-year-old male (UPN 06 in Supplementary  Table 1 and Supplementary Table 2 ) who was diagnosed as AML-NOS. Flow cytometry analysis revealed that blast cells were positive for CD13, CD33, CD56, CD34, CD45, MPO, and HLA-DR. Additionally, T cell-associated antigen CD7 was also expressed in 60.2% of blast cells. The patient received conventional induction therapy and achieved CR. After consolidation therapies were complete, AML relapsed. Although re-induction therapy was conducted, AML persisted (29.0% blast cells in BM). He directly proceeded to PB SCT from a haploidentical donor (his sister). The clinical course and conditioning regimen of this case is shown in Fig. 1 . We incorporated the ATGs at the beginning of the conditioning regimen with the aim of depleting host T-cells to facilitate engraftment in the setting of haploidentical SCT using posttransplant cyclophosphamide [30, 31] . After the administration of ATG at day −8, the number of AML blasts in PB drastically decreased from 2835/μL to 432/μL at day −7 (85% reduction). Neutrophil engraftment was achieved at day 16. At day 27, bone marrow aspiration confirmed complete remission. The patient still enjoys long-term RFS at around 4.5 years after haploidentical SCT.
Characteristics of 132 patients with relapsed/ refractory AML
Characteristics of the 132 patients with relapsed/refractory AML are summarized in Table 1 . The median age at SCT was 50 years (range, 19-68). In patients with AML whose tumor cells expressed CD7, a significantly greater percentage in the CD7-positive ATG group had a history of previous transplantation, received stem cells from a related HLA-mismatched BM/PBSC donor, and underwent a RIC regimen compared to the CD7-positive no-ATG group.
Clinical outcomes
The median follow-up period among survivors was 881 days (range, 192-4967 days) after allo-SCT. The probabilities of 2-year OS were 50.9% (95% confidence interval (CI) 23.6-72.9) in the CD7-positive ATG group, 10.5% (95% CI 2.8-24.4) in the CD7-positive no-ATG group, 12.0% (95% CI 2.1-31.5) in the CD7-negative ATG group, and 28.8% (95% CI 18.3-40.2) in the CD7-negative no-ATG group (CD7-positive ATG group vs. CD7-positive no-ATG group, P < 0.01; CD7-negative ATG group vs. CD7-negative no-ATG group, P = 0.20) (Fig. 2a) The putative anti-leukemic effects of ATGs against CD7 + AML... The P values for comparison among four groups AML-RGA acute myeloid leukemia with recurrent genetic abnormalities, AML-MRC acute myeloid leukemia with myelodysplasia-related changes, t-AML therapy-related acute myeloid leukemia, AML-NOS acute myeloid leukemia, not otherwise specified, HCT-CI hematopoietic cell transplantation-comorbidity index, MAC myeloablative conditioning, RIC reduced-intensity conditioning, CsA cyclosporine A, TAC tacrolimus in the CD7-positive ATG group, 6.2% (95% CI 1.1-18.1) in the CD7-positive no-ATG group, 10.5% (95% CI 1.8-28.4) in the CD7-negative ATG group, and 13.6% (95% CI 6.7-23.0) in the CD7-negative no-ATG group, respectively (CD7-positive ATG group vs. CD7-positive no-ATG group, P < 0.01; CD7-negative ATG group vs. CD7-negative no-ATG group, P = 0.62) (Fig. 2b) . Multivariate analysis showed that use of ATGs was significantly associated with superior OS and RFS in patients with CD7-positive AML (hazard ratio (HR) = 0.31, 95% CI 0.14-0.71, P < 0.01 for OS; and HR = 0.37, 95% CI 0.18-0.76, P < 0.01 for RFS, respectively) ( Table 2 ). The cumulative incidences of 2-year relapse/progression were 60.0% (95% CI 29.6-80.7) in the CD7-positive ATG group, 78.1% (95% CI 57.8-89.5) in the CD7-positive no-ATG group, 68.4% (95% CI 40.0-85.4) in the CD7-positive ATG group, and 65.2% (95% CI 52.1-75.5) in the CD7-negative no-ATG group (CD7-positive ATG group vs. CD7-positive no-ATG group, P = 0.05; CD7-negative ATG group vs. CD7-negative no-ATG group, P = 0.77) (Fig. 2c) . Multivariate analysis showed that use of ATGs was significantly associated with a lower risk of relapse/progression in patients with CD7-positive AML (HR = 0.20, 95% CI 0.08-0.52; P < 0.01) ( Table 2 ). The cumulative incidences of 2-year NRM were 13.3% (95% CI 2.0-35.5) in the CD7-positive ATG group, 15.6% (95% CI 5.4-30.8) in the CD7-positive no-ATG group, 21.1% (95% CI 6.0-42.2) in the CD7-negative ATG group, and 21.2% (95% CI 12.2-31.9) in CD7-negative no-ATG group (CD7-positive ATG group vs. CD7-positive no-ATG group, P = 0.72; CD7-negative ATG group vs. CD7-negative no-ATG group, P = 0.84) (Fig. 2d) . No significant differences were found among the four groups.
The cumulative incidences of grade II-IV aGvHD were 28.6% (95% CI 8.2-53.5) in the CD7-positive ATG group, 32.2% (95% CI 16.6-49.0) in the CD7-positive no-ATG group, 27.6% (95% CI 9.6-49.2) in the CD7-negative ATG group, and 50.0% (95% CI 36.8-61.8) in the CD7-negative no-ATG group (CD7-positive ATG group vs. CD7-positive no-ATG group, P = 0.71; CD7-negative ATG group vs. CD7-negative no-ATG group, P = 0.21) (Fig. 3a) . The cumulative incidences of grade III-IV aGvHD were 21.4% (95% CI 4.8-45.9) in the CD7-positive ATG group, 16.1% (95% CI 5.7-31.3) in the CD7-positive no-ATG group, 11.1% (95% CI 1.7-30.4) in the CD7-negative ATG group, and 17.9% (95% CI 9.4%-28.4%) in the CD7-negative no-ATG group (CD7-positive ATG group vs. CD7-positive no-ATG group, P = 0.68; CD7-negative ATG group vs. CD7-negative no-ATG group, P = 0.56) (Fig. 3b) . No significant differences were found among the four groups. The cumulative incidences of extensive cGvHD at 1 year were 33.3% (95% CI 11.3-57.5) in the CD7-positive ATG group, 18.8% (95% CI 7.2-34.4) in the CD7-positive no-ATG group, 5.3% (95% CI 0.2-23.8) in the CD7-negative ATG group, and 33.3% (95% CI 22.1-45.0) in the CD7-negative no-ATG group (CD7-positive ATG group vs. CD7-positive no-ATG group, P = 0.23; CD7-negative ATG group vs. CD7-negative no-ATG group, P = 0.01) (Fig. 3c) . The cumulative incidence of extensive cGvHD was significantly lower in the CD7-negative ATG group compared to the CD7-negative no-ATG group, whereas there was no significant difference between the CD7-positive ATG and CD7-positive no-ATG groups.
We also assessed the aberrant expression of other markers, including CD2, CD3, CD4, CD5, CD8, CD56, and CD79a (Supplementary Table 3 ). No expression of CD2, CD3, CD8, or CD79a was detected. In terms of the expression of CD4 or CD56, there was no statistically significant impact on clinical outcomes with the addition of ATG unlike the expression of CD7 (data not shown).
Discussion
Although ATG is widely used as in vivo T-cell depletion in allo-SCT, its anti-leukemic effect has not been elucidated in humans. Following our experience that AML blasts in the PB drastically decreased after the administration of ATG in a patient with CD7-positive AML, we retrospectively assessed the effects of ATG against CD7-positive AML in allo-SCT, since CD7 is one of the known target antigens of ATGs [9] . Our data showed that use of ATG in patients with CD7-positive AML was associated with a statistically superior OS and RFS, mainly as a result of lower incidence of relapse, whereas there was no impact on the clinical outcome in patients with CD7-negative AML. These results for the first time suggest the presence of anti-leukemic effects of ATG in CD7-positive AML, which led to a superior OS and RFS.
The CD7 antigen is generally considered a T cellassociated antigen that is expressed on the majority of mature T cells and a small subset of mature monocytes and macrophages. CD7 is aberrantly expressed in approximately 10% of AML cases [19] . It is known that CD7 is also transiently expressed in very early myeloid progenitors (with downregulation as these progenitors undergo differentiation and maturation), which could be one reason why some AML cases demonstrate CD7 expression [32] .
In our analysis, we included patients with relapsed/ refractory AML who underwent allo-SCT. A previous report [33] proposed a prognostic index to estimate 3-year OS in patients with relapsed/refractory AML who underwent allo-SCT. We applied this prognostic index in our cohort to determine whether the outcome of patients in the CD7-positive ATG group was favorable or not. According to this index, the expected probability of 3-year OS in the CD7-positive ATG group in our cohort was only 9.9% (95% CI 6.5-13.3). The actual probability of 3-year OS was 50.9% (95% CI 23.6-72.9), as shown in Fig. 2a . Therefore, the probability of OS in the CD7-positive ATG group was promisingly favorable. Considering the possibility that the presence of an extensive cGvHD might be leading to higher OS and lower RFS, we investigate the cumulative incidence of them. The incidence of extensive cGvHD in the CD7-positive ATG group tended to be higher when compared to that in the CD7-positive no-ATG group, but there was no significant difference between these two groups in this study, possibly due to a small number of cases in this study. Thus, it might be possible that higher incidence of extensive cGvHD had impacts on the clinical outcome. In this study, the choice of conditioning regimen including the dose of ATG was left to the discretion of the attending doctors. Therefore, it is necessary to carefully consider the possibility that the group who did not receive ATG might have a more advanced or higher risk disease and was offered transplant without ATG, although there is no statistically significant difference in the cytogenetic risk and percentage of blast in PB/BM among the groups as shown in Table 1 . To further clarify the benefit of ATGs in patients with CD7-positive AML, prospective studies that randomize the use of ATGs are needed.
No previous studies have observed any direct antileukemic effects of ATGs in patients who undergo allo-SCT, because ATGs are usually used late in conditioning regimens. In contrast, in our patient who demonstrated significant decreases in AML blasts in the PB after receiving ATGs, the ATGs were administered at the beginning of the conditioning regimen to facilitate engraftment in haploidentical SCT, allowing us to notice a possible antileukemic effect of ATGs against AML cells. One report [34] referred to the possibility of anti-leukemic effect of ATGs on AML cells in vivo in humans. The authors confirmed the cytotoxicity of ATGs against AML cells in vitro. The phenotype of AML cells in their study also expressed CD7. More in vitro experiments are needed to confirm the cytotoxicity of ATGs against AML, and to determine whether the aberrant expression of CD7 is an important determinant of such effects.
In terms of the impact of aberrant expression of CD7, CD7-positive AML represents a distinct biological and clinical subtype of AML and was found to be associated with adverse outcome [19, 21, 35] . In our analysis, the The putative anti-leukemic effects of ATGs against CD7 + AML... clinical outcome in the CD7-positive no-ATG group was significantly inferior to that in the CD7-negative no-ATG group, suggesting that aberrant expression of CD7 was an unfavorable risk factor for relapsed/refractory AML in the setting of allo-SCT. To the best of our knowledge, no previous studies have assessed the impact of CD7 in the setting of allo-SCT. Recently however, one study demonstrated the prognostic impact of CD25 in AML [16] . Unfortunately, we did not have any data about CD25 in our cohort. Future studies should assess the impact of ATGs in AML, incorporating the analysis of various aberrant surface markers including CD7 and CD25. Regarding the dose of ATGs, the dose commonly used in Japan is generally low-dose as previously reported [36] [37] [38] . In our study, in accordance with previous reports, the doses of ATGs were rather low. Anticipating the effects of ATGs as anti-leukemic antibodies, we may assume that higher doses of ATGs, which are usually used in Western countries [39, 40] , could be more effective than the dose used in our cohort. Considering the high incidence of relapse in this study, even in patients in the CD7-positive ATG group, the benefit of higher doses of ATGs should be explored.
The limitations of this study should be clarified. First, the major limitation was the low number of CD7-positive AML cases who received allo-SCT with ATGs as part of the conditioning regimen. Therefore, there might be a significant selection bias. Due to the retrospective nature of this study, we could not fully exclude uncontrolled confounding variables, even if we had conducted multivariate analyses for each clinical outcome. As our findings are still preliminary, the impact of CD7 and the use of ATGs should be re-evaluated in larger independent cohorts. Second, there was no direct evidence in in vitro experiments that CD7 was a major target of ATGs, as no viable cells were available. Future studies should incorporate in vitro approaches to confirm the anti-leukemic effects of ATGs and clarify the relevant mechanisms of ATG-mediated anti-leukemic effects, including antibody-dependent cell cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis. Third, we did not have data about many aberrantly expressed markers that are not routinely or practically stained. However, the expression of such untested lymphoid markers might contribute to the effects of ATG, and should be determined in the future.
In conclusion, our data showed that use of ATGs in patients with CD7-positive associated with statistically superior OS and RFS, mainly due to a lower incidence of relapse. These findings suggest the presence of anti- The putative anti-leukemic effects of ATGs against CD7 + AML...leukemic effects of ATGs in patients with CD7-positive benefit of ATGs in patients with CD7-positive be prospectively evaluated in future studies.
